Literature DB >> 16263822

Survival and death causes in differentiated thyroid carcinoma.

Carmen F A Eustatia-Rutten1, Eleonora P M Corssmit, Nienke R Biermasz, Alberto M Pereira, Johannes A Romijn, Johannes W Smit.   

Abstract

BACKGROUND: Survival studies in differentiated thyroid carcinoma (DTC) may be biased because they have been performed in heterogeneous populations. In addition, specific death causes in DTC have not been documented well in the literature. AIMS: The aim of our study was to investigate survival and specific death causes in a homogeneous cohort of DTC patients. PATIENTS: Patients included 366 consecutive patients with DTC who had all been treated according to the same protocol for initial therapy and follow-up.
METHODS: Prognostic factors for DTC-related death were analyzed by univariate Cox regression analysis, followed by stepwise multivariate Cox regression analysis. Standardized mortality rates (SMR) were calculated using normal mortality rates for the entire Dutch population.
RESULTS: During follow-up of 8.3 +/- 4.6 yr, 82 patients (22.4%) died. At multivariate Cox-regression analysis, tumor stage T4, distant metastases, and advanced age were associated with an increased relative risk for DTC-related death. SMR for the entire group was 2.32. This could be explained by increased SMR in patients with stage T4, distant metastases, or advanced age. Death causes could be verified in 80 patients: 52 died of DTC, 28 due to other causes. Ten of the 20 patients with stage T1-3M0 died from thyroid carcinoma.
CONCLUSION: Relative risk for thyroid cancer-related death and SMR are significantly increased in patients with stage T4 and M1 or advanced age. Although death risk is not increased in T1-3 M0 patients, DTC contributed significantly to mortality in all patient categories.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263822     DOI: 10.1210/jc.2005-1322

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  75 in total

1.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

2.  Rebound thymic hyperplasia detected by 18F-FDG PET/CT after radioactive iodine ablation therapy for thyroid cancer.

Authors:  Tae Joo Jeon; Yong Sang Lee; Jae-Hoon Lee; Hang Seok Chang; Young Hoon Ryu
Journal:  Thyroid       Date:  2014-08-20       Impact factor: 6.568

3.  Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues.

Authors:  Dan Chen; Wenjing Qi; Pengxin Zhang; Hongwei Guan; Lifen Wang
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

4.  EphB3 Stimulates Cell Migration and Metastasis in a Kinase-dependent Manner through Vav2-Rho GTPase Axis in Papillary Thyroid Cancer.

Authors:  Jing-Jing Li; Zhi-Jian Sun; Yan-Mei Yuan; Fen-Fen Yin; Yao-Gang Bian; Ling-Yun Long; Xue-Li Zhang; Dong Xie
Journal:  J Biol Chem       Date:  2016-12-16       Impact factor: 5.157

Review 5.  Multikinase inhibitors: a new option for the treatment of thyroid cancer.

Authors:  Matti L Gild; Martyn Bullock; Bruce G Robinson; Roderick Clifton-Bligh
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

6.  Lymphocyte-to-monocyte ratio prior to radioiodine ablation in low- and intermediate-risk, papillary thyroid cancer.

Authors:  Keunyoung Kim; Kyoungjune Pak; In-Joo Kim; Mijin Kim; Bo Hyun Kim; Byung-Joo Lee; Seong-Jang Kim
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

Review 7.  Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.

Authors:  Kenneth B Ain
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

Review 8.  Standard and emerging therapies for metastatic differentiated thyroid cancer.

Authors:  Christine J O'Neill; Jennifer Oucharek; Diana Learoyd; Stan B Sidhu
Journal:  Oncologist       Date:  2010-02-08

9.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

10.  Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer.

Authors:  Ning Qu; Ling Zhang; Wei-Li Wu; Qing-Hai Ji; Zhong-Wu Lu; Yong-Xue Zhu; Dao-Zhe Lin
Journal:  Tumour Biol       Date:  2016-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.